PMID: 8610987Feb 13, 1996Paper

Mechanisms of oral tolerance by MHC peptides

Annals of the New York Academy of Sciences
M H SayeghC B Carpenter

Abstract

Recent evidence indicates that MHC peptides play an important role in T-cell recognition of alloantigen. We studied the tolerogenicity of orally administered synthetic MHC allopeptides in the rat model. Initially, we demonstrated that oral administration of synthetic class II MHC allopeptides significantly inhibited the DTH response to the peptides as well as to donor-derived cells. The tolerogenic effect was antigen specific and was induced by immunogenic, but not by nonimmunogenic, allopeptides. Immunohistological studies of DTH skin lesions showed that oral tolerance is associated with a state of "immune deviation" to a predominance of Th2 cell function in the lesions. We recently extended the above observations and examined the tolerogenic effect of orally administered synthetic MHC allopeptides on MLR and CTL generation. We found that oral administration of the class II allopeptides effected significant reduction of MLR proliferation and CTL generation, which was antigen specific. In addition, similar to the DTH results when we compared the tolerogenicity of the immunogenic versus the nonimmunogenic peptides, MLR and CTL suppression was significantly higher with the immunogenic peptides. The gut immune system play an impor...Continue Reading

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M H SayeghC B Carpenter
Oct 1, 1991·The Journal of Experimental Medicine·A MillerH L Weiner
Feb 22, 1990·The New England Journal of Medicine·A M KrenskyP Parham
Jun 1, 1993·The Journal of Experimental Medicine·Z LiuN Suciu-Foca
Oct 1, 1994·Current Opinion in Immunology·A M Krensky, C Clayberger
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·A Friedman, H L Weiner
Mar 1, 1994·The Journal of Experimental Medicine·R S LeeH Auchincloss
Jan 1, 1994·Immunology Today·D A Shoskes, K J Wood
May 15, 1994·Transplantation·M H SayeghC B Carpenter
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·H AuchinclossL H Glimcher
Jan 1, 1996·International Reviews of Immunology·M H Sayegh, C B Carpenter

❮ Previous
Next ❯

Citations

Mar 15, 2002·Current Allergy and Asthma Reports·O Alpan
Mar 31, 1999·Immunology Today·D S Gould, H Auchincloss
Nov 22, 1997·Current Opinion in Immunology·C C Magee, M H Sayegh
Oct 14, 2003·International Immunopharmacology·Imed Ben NasserDaniel Tome
May 25, 2004·Nature Immunology·Oral AlpanPolly Matzinger
Jul 1, 2014·Human Immunology·Adam S A Gracon, David S Wilkes
Feb 27, 2007·Medical Hypotheses·M R Namazi
Dec 23, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·L Mayer
Apr 3, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·A L A DettinoM N Sato
Mar 27, 2003·Nature Reviews. Immunology·Matthias G von Herrath, Leonard C Harrison
Sep 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gary W HallerDavid H Sachs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.